However, the promise of drug from the human phase 1 trial came from a dose dependent reduction in FibroTest® (a biomarker test that uses the results of six blood serum tests to generate a score that has been showed to correlate with the degree of liver damage in people with a variety of liver diseases [9], believed to be as a result of a reduction in alpha- 2 macroglobulin levels. The gene discussed is A2M; the disease is liver disorder.